kamagra iskustva

formats

The UroLift® System

Published on July 13, 2017, by in Urolift.

The UroLift® System is a revolutionary treatment that provides rapid and durable relief from the bothersome urinary symptoms associated with BPH. Clinically proven to be safe and effective, the UroLift® System can improve symptoms 3 to 4 times greater than with medication, and patients can return to normal activity in a few days.

The UroLift® System is a new, minimally invasive approach to treating BPH for patients looking for an alternative to drug therapy or more invasive surgery. The UroLift System is a straightforward procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.

Clinical data has proven that the UroLift System treatment is safe and effective and can improve BPH symptoms 3 to 4 times greater than with medication1. Results have shown durability to two years with no impact to sexual function2. The goal is to relieve you of bothersome urinary symptoms so you can get back to your life and resume daily activities.

Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

Click here for more information about Urolift

formats

Local Urologist is helping to fight prostate cancer with studies of an innovative immuno-oncology approach – the ProstAtak® clinical trials

Published on October 4, 2016, by in Clinical Trials.
Prostate cancer is the second leading cause of cancer death among men in the United States. It is a common disease that effects 1 out of every 7 men. The good news is that early detection can assist in fighting this disease and scheduling annual prostate screenings can help identify this cancer in its early stages.
If cancer is detected in the prostate, various treatment options are available. Those options include active surveillance, surgery, radiation therapy, and hormone therapy. These are all good options, depending on the patient’s specific conditions, but no option is 100% effective for all patients.  There are also clinical trials that offer the hope of developing even more effective options for defeating prostate cancer.
One of these clinical trials is for ProstAtak®, a promising new immunotherapy that is being evaluated for localized prostate cancer.  ProstAtak is being developed by Advantagene, Inc., a Boston-area biopharmaceutical company, and is intended to “jump-start” the patient’s own immune system so it can better detect and destroy the patient’s unique cancer cells. In a Phase II study of ProstAtak® in combination with radiation therapy, the rate of recurrence was reduced from an expected 30% down to 10%.
Most recently, a multinational study has been launched to evaluate ProstAtak® as an immunotherapy addition to just monitoring during active surveillance, a form of “Proactive Surveillance™
Dr. Steven Sukin of Texas Urology Specialists is the only medical center in the Houston area that offers participation in the ProstAtak® clinical trial for patients choosing radiation therapy, and the first to offer it for patients under active surveillance. Dr Sukin is a leading Houston area urologist utilizing the most advanced treatment options for his patients. He has been practicing in the field of urology for more than fourteen years and has helped pioneer new procedures and treatments including the new BPH treatment, Urolift.
If you have been diagnosed with localized prostate cancer and are choosing either Active Surveillance or Radiation Therapy, you might be eligible to participate in one of two ProstAtak® clinical trials.    This innovative immunotherapy approach is meant to kill tumor cells and stimulate a cancer vaccine effect specific against the patient’s own tumor.
The two studies are:
Study One (For patients choosing radiation therapy):
Phase 3 Study of ProstAtak® with Standard Radiation Therapy for Localized Prostate Cancer (PrTK03).  This study is for patients that have not had surgery or radiation for prostate cancer and:
·       have intermediate-risk disease (any or all of the following: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c) or a single high risk feature (PSA>20 ng/ml, Gleason score 8-10, or T3a)
·       and are planning to receive standard external beam radiation therapy
Study Two (for patients choosing active surveillance):
Randomized Controlled Trial of ProstAtak® During Active Surveillance for Prostate Cancer (ULYSSES).  This study is for patients that are planning to be monitored on Active Surveillance rather than choosing radical treatment.
Interested patients can schedule a consultation with Dr. Steven Sukin at 281-351-5174 or visit his website regarding clinical trials at www.drstevensukinurology.com/prostatak-cancer-treatment.shtml
formats

New ProstAtak Clinical Trials

ProstAtak® is a new prostate cancer treatment trial for localized prostate cancer using gene therapy. This new cancer treatment trial is now available at our facilities and we are one of only two medical centers in the Houston area that offer this treatment trial.

Click here for more information about the treatment and how to sign up

Prostate Cancer
If you have been diagnosed with localized prostate cancer and are choosing Active Surveillance or Radiation Therapy, you might be eligible to participate in one of two clinical trials of an immunotherapy approach called ProstAtak®. ProstAtak kills tumor cells and stimulates a cancer vaccine effect.

The two studies are:
1. Phase 3 Study of ProstAtak® Immunotherapy with Standard Radiation Therapy for Localized Prostate Cancer (PrTK03). This study is for patients that have not had surgery or radiation for prostate cancer and:

  • have intermediate-risk disease (any or all of the following: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c) or a single high risk feature (PSA>20 ng/ml, Gleason score 8-10, or T3a)
  • and are planning to receive standard external beam radiation therapy

2. Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES). This study is for patients that have not had any prostate cancer treatment and:

  • are planning at this time to be monitored on Active Surveillance rather than choosing radical treatment.

Interested patients can schedule a consultation with Dr. Steven Sukin at 281-351-5174.

formats

A Cutting Edge BPH Treatment Option Called UroLift Is Making Waves In The Urology World and Dr. Steven Sukin Is Leading The Charge in Bringing This Revolutionary Procedure to Houston and Proctoring Doctors from around The Country

Published on August 9, 2016, by in Treatments.

A common medical condition that targets older men regarding the enlargement of the prostate gland is referred to as BPH or Benign prostate hyperplasia. Symptoms include a weak or slow urinary stream, a sense that you cannot completely empty your bladder, difficulty or delay in starting urination, an urgent feeling of needing to urinate as well as a urinary stream that stops and starts. This  condition affects over 70% of men in their 60s. BPH is not only treatable, but with the new UroLift  procedure being offered by Dr. Steven Sukin of Texas Urology Specialists, patients are now seeing extraordinary results from this minimally invasive procedure. Treatment options for men suffering  from BPH normally range from taking certain medications to more invasive methods that include surgery. Part of a patient’s prostate would typically need to be removed as part of that procedure. A new and minimally invasive option was introduced by the California-based company, NeoTract, Inc. 

NeoTract, Inc. specializes in developing minimally invasive and clinically effective urological devices. What is unique about the UroLift System is that it is the only system available that does not remove part of the patient’s prostate. It also does not negatively impact a man’s sexual function. The procedure involves the insertion of tiny implants that hold the enlarged prostate tissue back and relieves the compression on the urethra. The relief then allows for normal urine flow.

This is a cutting edge treatment option that Dr. Sukin helped bring to the Houston area. Not only has Dr. Sukin pioneered the use of this revolutionary treatment in The Woodlands, Tomball and North  Houston areas, he has also provided proctoring services to help train other doctors around the  country in this procedure. He is designated as the Houston proctor for UroLift. 

Recently, Dr. Sukin hosted urologists from Florida, Arkasas and Dallas. During their visit, Dr. Sukin explained how the UroLift procedure worked and trained each doctor on how to perform the UroLift  procedure. Dr. Sukin has a great team assembled in Houston and is excited to offer this procedure to his patients. He believes in providing men with the best treatment options available and the UroLift  System allows him to treat BPH with less invasive methods.

Dr. Sukin has been practicing in the field of urology for more than fourteen years. He is a leading  urologist in the Tomball, The Woodlands and North Houston areas. Please contact Dr. Sukin about your  BPH symptoms and allow him to discuss treatment options with you including the UroLift procedure. 

You can learn more about BPH and the UroLift procedure by going to the following website:

www.uroliftsintexas.com

formats

What is Benign Prostatic Hyperplasia, or BPH?

Published on August 3, 2016, by in Treatments.

Benign Prostatic Hyperplasia, or BPH, is a condition in which the prostate enlarges as men get older. Over 70% of men in their 60s have BPH symptoms so it is very common. While BPH is a benign condition and unrelated to prostate cancer, it can greatly affect a man’s quality of life.

The prostate is a male reproductive gland, about the size of a walnut, that produces fluid for semen. The prostate surrounds the urethra, which is the tube that carries urine from the bladder out of the body. As the prostate enlarges, it presses on and blocks the urethra, causing bothersome urinary symptoms such as:

  • Frequent need to urinate both day and night
  • Weak or slow urinary stream
  • A sense that you cannot completely empty your bladder
  • Difficulty or delay in starting urination
  • Urgent feeling of needing to urinate
  • A urinary stream that stops and starts

If you suffer from the above symptoms, you are not alone. BPH is one of the leading reasons for men to visit a urologist.

http://uroliftsintexas.com/what-is-bph/

formats

HIFU High Intensity Focused Ultrasound for Prostate Cancer

Published on March 7, 2016, by in Treatments.

What is HIFU?

HIFU stands for high intensity focused ultrasound, which is a minimally invasive technique for treating disease with precise, focused ultrasound waves that, when delivered, raise the temperature of the target tissue to nearly 195 degrees Fahrenheit in 2-3 seconds. This rapid-firing heat destroys the targeted tissue but leaves the surrounding tissue intact.


What is HIFU with the Sonablate® 500?

The Sonablate 500 (“Sonablate”) is medical device designed to treat prostate cancer and benign prostatic hyperplasia (“BPH”) with HIFU energy. The Sonablate captures real-time images of the prostate gland, allowing the physician to create a customized treatment plan for each patient. The physician then uses the Sonablate to deliver the ultrasound energy to extremely small target sites, or focal points, throughout the prostate gland. HIFU with the Sonablate (“Sonablate HIFU”) is a minimally invasive, outpatient treatment choice for prostate cancer; it does not involve surgery or radiation.


How exactly does Sonablate HIFU treat prostate disease?

Since HIFU destroys tissue at each targeted focal point throughout the prostate, the entire gland is ablated at the conclusion of the procedure, while healthy structures outside the gland remain unharmed.

HIFU uses non-ionizing, or clean, energy so the procedure may be repeated if necessary without damaging other tissue.


What are the results of the Sonablate HIFU treatment?

Sonablate HIFU has been used outside the United States for more than 10 years and international published studies show promising results as a cancer treatment that may well reduce risk for significant side effects, such as incontinence and impotence, often common with more aggressive modalities.


What are the recovery times and side effects of Sonablate HIFU for prostate cancer?

Patients can typically return to their normal lifestyle within a few days after the 2-4 hour procedure. Recovery involves wearing a catheter for approximately 2-3 weeks (varies according to each patient). All medical procedures have risks and benefits; all potential side effects and complications should be discussed with a physician prior to undergoing any procedure.


Does HIFU treat only the cancer cells? How?

Standard Sonablate HIFU treats the entire prostate gland by targeting tissue in overlapping treatment zones. The tissue is heated rapidly in targets, also known as lesions, throughout the entire gland until it is completely ablated.

Focal HIFU, on the other hand, involves treating only the cancerous part of the prostate with HIFU. Focal HIFU may be suitable for patients who have a single tumor within the gland or for patients with multiple tumors that all reside on the same side of the gland.


What is the history of HIFU and how long has it been used?

Research on HIFU began in the 1950s at Indiana University (IU) in Indianapolis, IN. In 1994, Dr. Michael Marberger and Dr. Stephan Madersbacher performed the first human prostate cancer study at the University of Vienna in Austria using the Sonablate® 200. They treated 29 human prostates in the body before performing a radical prostatectomy in order to see if the energy delivered was enough to destroy the targeted tissue. The study found that treatment could be performed safely and be repeated if necessary.

Other significant dates and milestones include:

  • 1995—a study done at IU showed that the whole prostate could be treated without damaging the prostate capsule or rectal wall.
  • 1999—Dr. Toyaki Uchida began treating patients using the Sonablate 200, the first generation of the Sonablate device.
  • 2001—The Sonablate 500 received its CE mark (approval for use) in Europe.
  • 2004—US HIFU was founded and began placing Sonablate devices in different areas where HIFU was approved or authorized. (Complete list of locations where Sonablate HIFU can be found is below.)
  • 2005—Health Canada approved the Sonablate 500.
  • 2006—The first Sonablate HIFU procedures were performed in Toronto, Canada.
  • 2008—Sonablate HIFU was first performed in India.
  • 2010—US HIFU gained European distribution rights for Sonablate technology.

Is Sonablate HIFU unique?

Scientists have engineered the Sonablate in an effort to provide a customized, effective and safe treatment.

Some unique Sonablate features include:

  • The Sonablate is the only HIFU device that can treat prostates up to 40 grams without an advance surgical procedure (known as a TURP) in order to achieve effective results.
  • Treating physicians are in control of the Sonablate’s power settings and can adjust them based on real-time feedback after delivery of the ultrasound energy, an innovative software feature known as TCM, or tissue change monitoring.
  • Each lesion produced by the Sonablate’s energy delivery is 10-12mm in length, smaller than other prostate cancer HIFU devices, which can allow for greater precision and conformity in small, critical spaces around the gland.
  • The Sonablate has real-time, three-dimensional imaging, enabling the physician to detect even slight movement of the device or gland, which could compromise treatment.
  • The Sonablate uses a fully integrated probe with two transducers, one to image the prostate gland and the other to treat with HIFU.

Where is Sonablate HIFU available now?

The Sonablate 500 is not approved for use in the U.S. It is investigational in this country and being studied for the treatment of prostate cancer in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of the Sonablate 500 for the treatment of prostate cancer.

Through International HIFU, one of US HIFU’s subsidiaries, U.S. patients and physicians travel each month to gain access to the technology in nearby offshore locations where it is already approved or authorized and available, including Nassau, Bahamas; Cancun and Puerto Vallarta, Mexico; Bermuda; and Toronto, Niagara Falls, Montreal and Winnipeg, Canada.

Sonablate HIFU can be found in additional areas such as Argentina, Australia, Brazil, China, Dominican Republic, Europe (Austria, France, Germany, Hungary, Italy, Romania, Russia, Spain, United Kingdom) India, Iran, Japan and Vietnam.

  • International HIFU is committed to creating a new standard for the treatment of prostate cancer and prostate disease with high intensity focused ultrasound (“HIFU”) therapy through the distribution and use of Sonablate®
  • International HIFU is a subsidiary of USHIFU, LLC (“US HIFU”), a privately held healthcare company focused on treating diseases, such as prostate cancer, with minimally invasive HIFU technologies. 500 (“Sonablate”) medical devices where approved, authorized or otherwise permitted for such uses outside the U.S.
  • HIFU for prostate cancer with the Sonablate (“Sonablate HIFU”) is not approved for commercial use in the U.S. It is investigational and being studied currently in two clinical trials, one for patients with recurrent prostate cancer following initial treatment with radiation (EBRT) and another for newly diagnosed patients who have not received any other treatment.
  • International HIFU’s treatment program enables U.S. patients and physicians to gain access to the technology in nearby offshore locations where it is already approved or authorized and available, including Nassau, Bahamas; Cancun and Puerto Vallarta, Mexico; Bermuda; and Toronto, Niagara Falls, Montreal and Winnipeg, Canada.
  • Sonablate HIFU can be found in additional areas such as Argentina, Australia, Brazil, China, Dominican Republic, Europe (Austria, France, Germany, Hungary, Italy, Romania, Russia, Spain, United Kingdom) India, Iran, Japan and Vietnam.

HIFU—about the energy

  • When HIFU energy is delivered to a specific location within the body, the tissue temperature at that site, or focal point, is elevated to nearly 195 degrees Fahrenheit in a matter of seconds, resulting in tissue destruction.
  • Tissue outside the focal point remains unharmed.
  • Unlike radiation, HIFU uses clean, or non-ionizing, energy, so the procedure may be repeated if necessary without damaging healthy tissue.
  • HIFU is being studied around the world to treat all types of cancer and soft tissue diseases.

HIFU—with the Sonablate 500

  • Focus Surgery, Inc., another US HIFU subsidiary, developed the Sonablate system to treat localized prostate cancer and benign prostatic hyperplasia (“BPH”) with HIFU in countries where it is approved or authorized for use.
  • During Sonablate HIFU, physicians obtain real-time ultrasound images of the prostate and surrounding areas. From these images, they can create a customized plan for delivering the ultrasound energy. The Sonablate software allows physicians to precisely define the treatment zones in order to treat all prostatic tissue in the gland.
  • Sonablate HIFU is minimally invasive, performed on an outpatient basis and typically lasts 2-4 hours, depending on the size of the prostate. There is no surgery or radiation involved. Patients wear a catheter post-procedure but are able to resume normal activities almost immediately.
  • The Sonablate can treat prostates up to 40 grams without an advance surgical procedure (known as a TURP) in order to achieve effective results.
  • The Sonablate incorporates three-dimensional imaging for enhanced visualization.
  • The newest technological enhancement to the Sonablate is called TCM, or tissue change monitoring, which gives real-time feedback to the physician regarding changes in tissue both before and after HIFU is delivered.
  • There are nearly 400 trained Sonablate users worldwide.
  • More than 9,000 patients have undergone Sonablate HIFU outside the U.S.
  • The Sonablate 500 is not approved for use in the U.S. The Sonablate 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate 500 for the treatment of prostate cancer.

Click here to learn more about HIFU

formats

Houston doctor, patient lead the way in cancer vaccine study

Published on January 8, 2015, by in Interviews.

Read full story

formats

Urolift for BPH

Published on November 11, 2014, by in Treatments.

What is Urolift?

The UroLift® System is a revolutionary treatment that provides rapid and durable relief from the bothersome urinary symptoms associated with BPH. Clinically proven to be safe and effective, the UroLift System can improve symptoms 3 to 4 times greater than with medication,5 and patients can return to normal activity in a few days.

How does the UroLift® System work?

The doctor places small, permanent implants into the prostate to lift and hold the enlarged tissue out of the way, relieving pressure on the urethra and allowing urine to flow. There is no cutting, heating, or removal of prostate tissue required which means a minimally invasive, straightforward procedure and less downtime for patients.

 

The small UroLift Implant is made from commonly used implantable materials. Typically, 4-5 implants are used per patient.



 

Questions and Answers

How soon will I feel better after having the UroLift® System treatment?
Patients may experience improvement in their lower urinary tract symptoms as early as 2 weeks after the procedure.

Will it affect my sexual function?
There have been no reports of erectile dysfunction or ejaculatory dysfunction as a result of the UroLift System treatment.

What happens during the recovery period?
There is minimal downtime post-procedure and patients may experience symptom relief in as early as 2 weeks.* Typically, no overnight stay and no catheter is required but you may experience urinary discomfort during the recovery period. Your doctor will discuss with you how quickly you can return to your daily activities.

What clinical data is available for the UroLift System? 
There is a large amount of data from clinical studies conducted in the US, Canada, Europe and Australia that has been presented in peer-reviewed medical publications demonstrating the safety and effectiveness of the UroLift System. To learn more about the clinical data available, visit urolift.com/clinical-data.html


 

Click here to download BPH Treatment Benefits Comparison

Click here to download Urolift brochure

formats

Prostiva RF Therapy

Published on April 6, 2014, by in Treatments.

Prostiva® RF Therapy (Prostiva) is a safe, effective, in-office treatment that that provides long-term relief from BPH symptoms and urinary obstruction. Prostiva is appropriate for men experiencing moderate to severe BPH symptoms especially patients who do not want to take daily medications for the rest of their lives, dislike the side effects and ongoing costs of medication or do not want the risks, side effects or high costs of surgery.

Because it provides direct visualization of the anatomy during the procedure, Prostiva treats the median and lateral lobe as well as asymmetrical prostates.
How does it work

Benefits

Risks

Prostiva® Website

 

Contact Information

Call us at 281.351.5174 to get more information regarding Prostiva® RF Therapy.

formats

Greenlight Laser PVP

Published on March 31, 2014, by in Uncategorized.

What is Greenlight PVP?

Greenlight PVP is an advanced laser procedure used to precisely remove enlarged prostate tissue. PVP stands for “Photoselective Vaporization of the Prostate”. This procedure gets its name from the high powered “green laser” used to vaporize the prostate tissue.

Contact Information

Call us at 281.351.5174 to get more information regarding the Greenlight PVP procedure.

 

Resources:

- Laser PVP Surgery – Mayo Clinic

- Greenlight Website